Track the latest insights on doxepin HCL price trend and forecast with detailed analysis of regional fluctuations and market dynamics across North America, Latin America, Central Europe, Western Europe, Eastern Europe, Middle East, North Africa, West Africa, Central and Southern Africa, Central Asia, Southeast Asia, South Asia, East Asia, and Oceania.

Get real-time access to monthly/quarterly/yearly prices Request Sample
During the third quarter of 2025, the doxepin HCL prices in the USA reached 176,460 USD/MT in September. Prices rose as pharmaceutical hubs expanded procurement and feedstock availability steadied. Inland transport congestion caused minor delays, and contract manufacturers increased scheduled offtake, encouraging more orderly sourcing.
During the third quarter of 2025, the doxepin HCL prices in China reached 157,024 USD/MT in September. The upward movement followed tighter production planning at API facilities and firm export interest. Port-handling delays affected outbound flow, while downstream formulators aligned purchases with consistent output requirements.
During the third quarter of 2025, the doxepin HCL prices in Germany reached 179,101 USD/MT in September. Prices increased as local healthcare manufacturing strengthened and import-driven facilities saw staggered shipment timings. Slight tightening in specialty input access encouraged more deliberate procurement among larger formulators.
During the third quarter of 2025, the doxepin HCL prices in Japan reached 158,935 USD/MT in September. Prices strengthened as formulation plants elevated restocking and exchange-rate-sensitive import costs shaped ordering. Port-side berth variability influenced unloading times, prompting more careful coordination of incoming shipments.
During the third quarter of 2025, the doxepin HCL prices in France reached 182,456 USD/MT in September. The upward movement reflected stable medicine output and localized tightness across distributor networks. Buyers diversified supply sources and adjusted scheduling to secure material amid shifting channel availability.
During the second quarter of 2025, the doxepin HCL prices in the USA reached 172,814 USD/MT in June. Contracting routines guided purchasing volumes, while production variability affected inflows to distributors. Logistics inconsistencies required schedule adjustments, shaping a steady, efficiency-focused procurement environment.
During the second quarter of 2025, the doxepin HCL prices in China reached 154,096 USD/MT in June. API facilities adjusted operations, influencing availability for domestic and export markets. Freight timing volatility at major ports shaped buyer planning, while downstream formulators balanced inventories with revised production schedules.
During the second quarter of 2025, the doxepin HCL prices in Germany reached 175,572 USD/MT in June. Consistent healthcare demand supported transactional activity, and formulators recalibrated procurement to align with processing needs. Varied import lead times encouraged more careful inventory management across facilities.
During the second quarter of 2025, the doxepin HCL prices in Japan reached 157,533 USD/MT in June. Downstream manufacturers adjusted production cycles and managed uneven shipment flow. Currency-linked considerations influenced import planning, contributing to measured purchasing behavior.
During the second quarter of 2025, the doxepin HCL prices in France reached 180,453 USD/MT in June. Distributor-level availability fluctuated, prompting formulators to align orders with evolving supply access. These adjustments supported stable procurement in line with domestic pharmaceutical needs.
The report provides a detailed analysis of the market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of FOB and CIF prices, as well as the key factors influencing the doxepin HCL prices.
Q3 2025:
As per the doxepin HCL price index, prices increased as procurement strengthened across major formulation hubs and select intermediates showed tighter availability. Rail and road transit variability in central and northern Europe encouraged manufacturers to maintain broader inventory buffers and diversify inbound routes. Pharmaceutical producers leaned on more stable import corridors as freight scheduling grew less predictable, especially for controlled-substance APIs. Consistent offtake from mental-health medicine lines supported firmer sentiment, shaping disciplined sourcing across the region.
Q2 2025:
Market activity was shaped by steady demand from regulated pharmaceutical manufacturers and intermittent variability in imported API access. Formulators adjusted procurement schedules to cope with uneven raw-material flows at major continental entry points, and distributors adapted warehousing practices to smooth intake volumes. Regulatory compliance and quality-assurance checks continued to guide sourcing choices, encouraging structured acquisition routines aligned with production planning.
This analysis can be extended to include detailed doxepin HCL price information for a comprehensive list of countries.
| Region | Countries Covered |
|---|---|
| Europe | Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal, and Greece, among other European countries. |
As per the doxepin HCL price index, prices moved higher as formulation units increased orders and distribution channels encountered selective constraints. Freight congestion along key west-to-central corridors created delays in material repositioning, prompting buyers to extend planning horizons. API plants adjusted production around evolving contract loads, maintaining controlled output to suit consistent downstream requirements. These logistics and manufacturing dynamics encouraged risk-aware procurement strategies across the region.
Q2 2025:
In North America, operational stability at leading API producers underpinned consistent allocation planning for doxepin HCL across hospital and contract-manufacturing channels. Buyers emphasized continuity of supply, aligning orders with predictable manufacturing cycles and controlled output from domestic facilities. Logistics providers maintained focus on reliability, coordinating inland freight and port operations to support steady material distribution.
Specific doxepin HCL historical data within the United States and Canada can also be provided.
| Region | Countries Covered |
|---|---|
| North America | United States and Canada |
As per doxepin HCL price chart, the prices in the Middle East and Africa fluctuated due to a complex interplay of factors, primarily driven by supply chain disruptions, seasonal demand shifts, and geopolitical influences.
Q2 2025:
The report explores the doxepin HCL pricing trends and doxepin HCL price chart in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.
In addition to region-wise data, information on doxepin HCL prices for countries can also be provided.
| Region | Countries Covered |
|---|---|
| Middle East & Africa | Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco, among other Middle Eastern and African countries. |
Q3 2025:
Prices strengthened as major API production hubs in East and South Asia adjusted operations amid evolving feedstock and processing conditions. Import-dependent economies across Southeast Asia faced inconsistent landed costs and irregular cargo arrival patterns, prompting phased and closely timed procurement cycles. Large-scale formulation clusters in India, China, and Japan sustained high offtake, reinforcing regional demand. These factors encouraged buyers to adopt more strategic sourcing approaches across multiple supply origins.
Q2 2025:
Across Asia Pacific, sourcing behavior reflected a mix of robust offtake in large formulation centers and uneven inventory positions at smaller manufacturing hubs. Procurement timing was coordinated to match plant-level operational rhythms, and import-dependent markets factored freight cost variability into sourcing decisions. The combined influence of local production dynamics and cross-border logistics encouraged a layered approach to supply assurance.
This doxepin HCL price analysis can be expanded to include a comprehensive list of countries within the region.
| Region | Countries Covered |
|---|---|
| Asia Pacific | China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand, among other Asian countries. |
Q3 2025:
Latin America's doxepin HCL market is predominantly influenced by its rich natural reserves, particularly in countries like Chile and Brazil. However, political instability and inconsistent regulatory frameworks can lead to significant volatility in doxepin HCL prices.
Q2 2025:
Infrastructure challenges and logistical inefficiencies often impact the supply chain, affecting Latin America’s ability to meet international demand consistently. Moreover, the doxepin HCL price index, economic fluctuations, and currency devaluation are critical factors that need to be considered when analyzing doxepin HCL pricing trends in this region.
This comprehensive review can be extended to include specific countries within the region.
| Region | Countries Covered |
|---|---|
| Latin America | Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru, among other Latin American countries. |
IMARC's latest publication, “Doxepin HCL Prices, Trend, Chart, Demand, Market Analysis, News, Historical and Forecast Data Report 2025 Edition,” presents a detailed examination of the doxepin HCL market, providing insights into both global and regional trends that are shaping prices. This report delves into the spot price of doxepin HCL at major ports and analyzes the composition of prices, including FOB and CIF terms. It also presents detailed doxepin HCL prices trend analysis by region, covering North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The factors affecting doxepin HCL pricing, such as the dynamics of supply and demand, geopolitical influences, and sector-specific developments, are thoroughly explored. This comprehensive report helps stakeholders stay informed with the latest market news, regulatory updates, and technological progress, facilitating informed strategic decision-making and forecasting.

The global doxepin HCL industry size reached USD 507.22 Million in 2025. By 2034, IMARC Group expects the market to reach USD 671.05 Million, at a projected CAGR of 3.16% during 2026-2034. Growth is supported by rising therapeutic use in mental-health treatment, expanding pharmaceutical production capacities, and steady uptake of tricyclic antidepressants across both established and emerging healthcare markets.
Latest News and Developments:
Doxepin HCL is classified as a tricyclic antidepressant medication. It functions by assisting in bringing back the balance of specific natural chemicals in the brain. It can be found in various forms such as oral tablets, oral capsules, oral solutions, and topical creams. It works by elevating the levels of serotonin (5-hydroxytryptamine or 5-HT) and norepinephrine (NE) in the brain.
Additionally, doxepin HCL exhibits an inhibitory impact on the central nervous system (CNS) by obstructing histamine (H1), α1 adrenergic, and muscarinic receptors. It widens the drug's range of uses by blocking sodium and potassium channels in heart muscle cells. The US Food and Drug Administration (FDA) has given its approval for the treatment of major depressive disorder, anxiety, insomnia, and skin pruritus.
| Key Attributes | Details |
|---|---|
| Product Name | Doxepin HCL |
| Report Features | Exploration of Historical Trends and Market Outlook, Industry Demand, Industry Supply, Gap Analysis, Challenges, Doxepin HCL Price Analysis, and Segment-Wise Assessment. |
| Currency/Units | US$ (Data can also be provided in local currency) or Metric Tons |
| Region/Countries Covered | The current coverage includes analysis at the global and regional levels only. Based on your requirements, we can also customize the report and provide specific information for the following countries: Asia Pacific: China, India, Indonesia, Pakistan, Bangladesh, Japan, Philippines, Vietnam, Thailand, South Korea, Malaysia, Nepal, Taiwan, Sri Lanka, Hongkong, Singapore, Australia, and New Zealand* Europe: Germany, France, United Kingdom, Italy, Spain, Russia, Turkey, Netherlands, Poland, Sweden, Belgium, Austria, Ireland, Switzerland, Norway, Denmark, Romania, Finland, Czech Republic, Portugal and Greece* North America: United States and Canada Latin America: Brazil, Mexico, Argentina, Columbia, Chile, Ecuador, and Peru* Middle East & Africa: Saudi Arabia, UAE, Israel, Iran, South Africa, Nigeria, Oman, Kuwait, Qatar, Iraq, Egypt, Algeria, and Morocco* *The list of countries presented is not exhaustive. Information on additional countries can be provided if required by the client. |
| Information Covered for Key Suppliers |
|
| Customization Scope | The report can be customized as per the requirements of the customer |
| Report Price and Purchase Option |
Plan A: Monthly Updates - Annual Subscription
Plan B: Quarterly Updates - Annual Subscription
Plan C: Biannually Updates - Annual Subscription
|
| Post-Sale Analyst Support | 360-degree analyst support after report delivery |
| Delivery Format | PDF and Excel through email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Benefits for Stakeholders:
IMARC offers trustworthy, data-centric insights into commodity pricing and evolving market trends, enabling businesses to make well-informed decisions in areas such as procurement, strategic planning, and investments. With in-depth knowledge spanning more than 1000 commodities and a vast global presence in over 150 countries, we provide tailored, actionable intelligence designed to meet the specific needs of diverse industries and markets.
1000
+Commodities
150
+Countries Covered
3000
+Clients
20
+Industry
IMARC delivers precise commodity pricing insights using proven methodologies and a wealth of data to support strategic decision-making.
Our extensive databases provide detailed commodity pricing, import-export trade statistics, and shipment-level tracking for comprehensive market analysis.
Through direct supplier surveys and expert interviews, we gather real-time market data to enhance pricing accuracy and trend forecasting.
We analyze industry reports, trade publications, and market studies to offer tailored intelligence and actionable commodity market insights.
Trusted by 3000+ industry leaders worldwide to drive data-backed decisions. From global manufacturers to government agencies, our clients rely on us for accurate pricing, deep market intelligence, and forward-looking insights.